Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Related Articles
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
Pandemic Cancer Incidence Observance Shows Further Recovery Still Needed
A study observed differences between expected and observed cancer incidence in 2020 and 2021 to evaluate the pandemic’s disruption of cancer detection.
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis
This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based on the time…
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Role of renal mass biopsy for diagnosis and management: Review of current trends and future directions
There is greater recognition for the role of renal mass biopsy (RMB) in guiding patient management and, although practices vary between institutions, the overall use…
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC
Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma
Welcome! You are invited to join a webinar: Post-ASH 2024 MPN highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading experts on MPN present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current…
Summer Internship Program (SIP)
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.